The major objective of this study is to conduct a double-blind, placebo-controlled, randomized clinical trial to assess whether oral alpha lipoic acid supplementation will decrease cardiovascular disease and type 2 diabetes risk in obese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
70
1200 mg/day
1200 mg/day
Xinjiang Medical University
Ürümqi, Xinjiang, China
Biomarkers of oxidative stress
Time frame: 2 months
Insulin sensitivity
Time frame: 2 months
Endothelial function
Time frame: 2 months
Inflammatory markers
Time frame: 2 months
Blood pressure
Time frame: 2 months
Fasting lipid profile
Time frame: 2 months
Pulse wave velocity
Time frame: 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.